Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths

Affiliations

¹ Brandon del Pozo, Ph.D., M.P.A., M.A., is a Postdoctoral Fellow, Miriam Hospital/Warren Alpert Medical School of Brown University, and Research Fellow, Global Law Enforcement and Public Health Association Lawrence S. Krasner, J.D., is the District Attorney of Philadelphia. Sarah F. George, J.D., is a a State's Attorney, Chittenden County, Vermont.

Brandon Del Pozo et al. J Law Med Ethics. 2020 Jun.

. 2020 Jun;48(2):373-375.

doi: 10.1177/1073110520935353.

¹ Brandon del Pozo, Ph.D., M.P.A., M.A., is a Postdoctoral Fellow, Miriam Hospital/Warren Alpert Medical School of Brown University, and Research Fellow, Global Law Enforcement and Public Health Association Lawrence S. Krasner, J.D., is the District Attorney of Philadelphia. Sarah F. George, J.D., is a a State's Attorney, Chittenden County, Vermont.

No abstract available

References

1. Wakeman SE and Rich JD, “Barriers to Medications for Addiction Treatment: How Stigma Kills,” Substance Use & Misuse 53, no. 2 (2018): 330–333. - PubMed
1. Velander JR, “Suboxone: Rationale, Science, Misconceptions,” The Ochsner Journal 18, no. 1 (2018): 23–29. - PMC - PubMed
1. Doernberg M, Krawczyk N, Agus D, and Fingerhood M, “Demystifying Buprenorphine Misuse: Has Fear of Diversion Gotten in the Way of Addressing the Opioid crisis?” Substance Abuse 40, no. 2 (2019): 148–153. - PMC - PubMed
1. Id.
1. Andraka-Christou B and Capone MJ, “A Qualitative Study Comparing Physician-Reported Barriers to Treating Addiction Using Buprenorphine and Extended-Release Naltrexone in U.S. Office-Based Practices,” International Journal of Drug Policy 54 (2018): 9–17. - PubMed